Medical professionals and researchers continuously seek innovative methods to mitigate the severe consequences of Neonatal Brain Injury. Recently, a groundbreaking clinical study conducted at Semmelweis University in Hungary demonstrated a novel approach to treating newborns affected by hypoxic-ischemic encephalopathy. By utilizing Intranasal Breast Milk Therapy, researchers have opened a new frontier in neonatal neuroprotection. This article examines the methodology, challenges, and implications of this recent clinical trial published in the prestigious journal Pediatric Research.
Understanding Hypoxic-Ischemic Encephalopathy in Newborns
Hypoxic-ischemic encephalopathy (HIE) remains one of the most significant causes of neonatal mortality and long-term neurological damage globally. This condition occurs when a newborn’s brain suffers from a sudden lack of oxygen and impaired blood supply, typically during a complicated labor or delivery process. The resulting cellular damage can lead to severe developmental delays, cerebral palsy, and cognitive deficits if not addressed immediately.
Currently, the international standard of care for moderate to severe HIE is therapeutic hypothermia. This treatment involves carefully reducing the infant’s body temperature to approximately 33–34°C for several days. Cooling the brain decreases its metabolic rate, reduces cellular energy demands, and limits the cascade of apoptotic cell death triggered by the initial oxygen deprivation. While therapeutic hypothermia has significantly improved outcomes, it is not a cure. Many infants still experience lasting neurological impairments, necessitating the development of adjunctive therapies that actively repair damaged neural tissue.
Schedule a free consultation to learn more about advancements in neonatal care and neuroprotective strategies.
The Biological Mechanism Behind Intranasal Breast Milk Treatment
The scientific rationale for Breast Milk Treatment extends far beyond standard infant nutrition. Fresh human breast milk is a highly complex biological fluid containing a myriad of bioactive components, including stem cells, immune cells, cytokines, and neurotrophic factors. Neurotrophic factors, in particular, play a critical role in supporting the survival, development, and regeneration of neurons.
Traditionally, when a baby feeds orally, these beneficial components must survive the harsh acidic environment of the gastrointestinal tract before entering the bloodstream. However, the Intranasal Breast Milk Therapy developed in Hungary leverages a direct anatomical pathway. By administering the milk into the nasal passages, the bioactive components bypass the blood-brain barrier and the digestive system entirely. The olfactory and trigeminal nerves in the nasal cavity provide a direct conduit to the central nervous system, allowing stem cells and neurotrophic factors to reach the site of brain injury rapidly and in higher concentrations.
Breakdown of the Semmelweis University Clinical Trial
Conducted between December 2024 and February 2025, this clinical study represents the first documented use of this specific Intranasal Breast Milk Therapy in brain-injured newborns in Hungary. Led by Dr. Ünőke Méder, an assistant professor at the Department of Pediatrics, and Dr. Eszter Tarjányi, a pediatric resident, the study focused on infants diagnosed with moderate to severe hypoxic-ischemic brain injury.
The clinical protocol required the newborns to receive standard therapeutic hypothermia alongside the experimental breast milk treatment. Within the first 48 hours of life, freshly expressed breast milk from the infant’s own mother was administered into the nostrils under strict clinical supervision. The treatment continued for a total of 28 days. To assess the feasibility of long-term application, properly trained parents were integrated into the care protocol to administer the Breast Milk Treatment in a controlled home environment after the initial hospitalization phase.
Submit your application today to join leading medical institutions researching pediatric neurology and neonatal care.
Managing Logistical and Emotional Complexities
Executing a novel clinical trial involving fresh biological material presents unique logistical hurdles. Dr. Méder highlighted that transporting the breast milk and organizing continuous care proved exceptionally challenging. Researchers had to ensure the timely collection of freshly expressed milk, sometimes traveling to highly remote locations. For instance, medical personnel navigated difficult terrain to collect milk from a farm near Cegléd, a town situated 80 kilometers from Budapest, where standard taxi services refused to travel due to the lack of proper roads.
Beyond the physical logistics, the research team had to address the psychological trauma experienced by the mothers. Giving birth to a child that requires immediate intensive care is highly distressing. Initiating and maintaining a regular milk expression schedule under such emotional duress required substantial psychological support, lactation consulting, and empathy from the clinical staff.
Integrating Parents into the Clinical Protocol
Despite the initial apprehension regarding parental involvement, the researchers found that incorporating parents into the treatment regimen was highly successful. Parents of critically ill newborns often feel helpless; providing them with a tangible, active role in their child’s neurological recovery fostered a sense of control and purpose.
According to Dr. Tarjányi, the training process was straightforward. Once parents understood the anatomical rationale for the Intranasal Breast Milk Therapy and were reassured that the administration process did not cause pain to the infant, they applied the procedure with confidence. This dynamic not only supported the clinical trial but also strengthened the parent-infant bond during a highly stressful neonatal intensive care unit (NICU) stay.
Have questions about the methodology of this clinical trial? Write to us!
Evaluating the Safety of Breast Milk Treatment
It is crucial to note that the primary objective of this Semmelweis University study was to establish the safety and feasibility of the Intranasal Breast Milk Therapy, not to definitively prove its efficacy in reversing brain damage. The results were highly promising regarding safety. Over the course of the 28-day treatment period, the ten participating newborns experienced no respiratory, circulatory, or neurological complications directly attributable to the nasal administration of breast milk.
This safety profile is paramount. Any adjunctive therapy introduced to vulnerable, brain-injured neonates must first do no harm. By confirming that the nasal delivery of fresh milk is well-tolerated, researchers have successfully cleared the initial barrier required to proceed with larger, more comprehensive studies.
Explore our related articles for further reading on neuroprotective strategies in neonatal medicine.
International Precedents and Future Efficacy Studies
The Semmelweis University trial does not exist in a vacuum. Prior to this human study, the concept of intranasal breast milk had been explored in animal models. Furthermore, clinical studies conducted in Germany and Canada previously utilized similar intranasal methods on preterm infants who had suffered brain hemorrhages. Those international studies suggested beneficial effects on the nervous system, providing a strong foundation for the Hungarian research team.
Moving forward, the medical community requires large-scale, randomized, and controlled studies to definitively measure the neuroprotective efficacy of this Breast Milk Treatment. Researchers must track the long-term neurological outcomes of these children to determine if the intranasal delivery of stem cells and neurotrophic factors quantifiably reduces the incidence of cerebral palsy and cognitive impairments compared to therapeutic hypothermia alone.
Potential Applications in Developing Nations
One of the most compelling aspects of Intranasal Breast Milk Therapy is its potential global accessibility. Therapeutic hypothermia requires specialized, expensive cooling equipment, continuous electrical power, and highly trained intensive care staff. In many developing countries, these resources are scarce, leaving infants with Neonatal Brain Injury without access to the standard of care.
If future studies confirm the efficacy of intranasal breast milk, it could serve as a low-cost, highly accessible alternative or adjunctive therapy in resource-limited settings. The raw material (the mother’s own milk) is readily available, and the administration method requires minimal equipment. Several countries have already expressed interest in the method developed in Hungary, recognizing its potential to democratize access to neonatal neuroprotection.
The Future of Neonatal Neuroprotection
The first clinical use of Intranasal Breast Milk Therapy for Neonatal Brain Injury at Semmelweis University marks a significant milestone in pediatric medicine. By successfully demonstrating the safety of delivering fresh breast milk directly to the central nervous system via the nasal passages, researchers have established a viable new framework for neonatal care. As the scientific community awaits the results of subsequent efficacy trials, this innovative approach stands as a testament to the untapped therapeutic potential of human biology and the relentless pursuit of better outcomes for the most vulnerable patients.
Share your experiences in the comments below regarding innovative neonatal therapies and parental involvement in clinical care.
